S&P 500   3,608.82 (-0.87%)
DOW   28,883.70 (-1.17%)
QQQ   269.07 (-1.03%)
AAPL   139.70 (-1.95%)
MSFT   235.01 (-1.05%)
META   136.55 (+0.10%)
GOOGL   96.23 (-1.22%)
AMZN   113.84 (-0.84%)
TSLA   266.91 (-0.48%)
NVDA   122.62 (+0.34%)
NIO   15.84 (+1.67%)
BABA   80.61 (+1.96%)
AMD   63.93 (-0.33%)
T   15.44 (-0.58%)
MU   50.65 (+1.28%)
CGC   2.75 (-1.08%)
F   11.27 (-1.74%)
GE   62.19 (-0.86%)
DIS   95.13 (-2.38%)
AMC   7.05 (-0.70%)
PYPL   86.68 (-2.28%)
PFE   44.07 (-0.20%)
NFLX   236.63 (-1.28%)
S&P 500   3,608.82 (-0.87%)
DOW   28,883.70 (-1.17%)
QQQ   269.07 (-1.03%)
AAPL   139.70 (-1.95%)
MSFT   235.01 (-1.05%)
META   136.55 (+0.10%)
GOOGL   96.23 (-1.22%)
AMZN   113.84 (-0.84%)
TSLA   266.91 (-0.48%)
NVDA   122.62 (+0.34%)
NIO   15.84 (+1.67%)
BABA   80.61 (+1.96%)
AMD   63.93 (-0.33%)
T   15.44 (-0.58%)
MU   50.65 (+1.28%)
CGC   2.75 (-1.08%)
F   11.27 (-1.74%)
GE   62.19 (-0.86%)
DIS   95.13 (-2.38%)
AMC   7.05 (-0.70%)
PYPL   86.68 (-2.28%)
PFE   44.07 (-0.20%)
NFLX   236.63 (-1.28%)
S&P 500   3,608.82 (-0.87%)
DOW   28,883.70 (-1.17%)
QQQ   269.07 (-1.03%)
AAPL   139.70 (-1.95%)
MSFT   235.01 (-1.05%)
META   136.55 (+0.10%)
GOOGL   96.23 (-1.22%)
AMZN   113.84 (-0.84%)
TSLA   266.91 (-0.48%)
NVDA   122.62 (+0.34%)
NIO   15.84 (+1.67%)
BABA   80.61 (+1.96%)
AMD   63.93 (-0.33%)
T   15.44 (-0.58%)
MU   50.65 (+1.28%)
CGC   2.75 (-1.08%)
F   11.27 (-1.74%)
GE   62.19 (-0.86%)
DIS   95.13 (-2.38%)
AMC   7.05 (-0.70%)
PYPL   86.68 (-2.28%)
PFE   44.07 (-0.20%)
NFLX   236.63 (-1.28%)
S&P 500   3,608.82 (-0.87%)
DOW   28,883.70 (-1.17%)
QQQ   269.07 (-1.03%)
AAPL   139.70 (-1.95%)
MSFT   235.01 (-1.05%)
META   136.55 (+0.10%)
GOOGL   96.23 (-1.22%)
AMZN   113.84 (-0.84%)
TSLA   266.91 (-0.48%)
NVDA   122.62 (+0.34%)
NIO   15.84 (+1.67%)
BABA   80.61 (+1.96%)
AMD   63.93 (-0.33%)
T   15.44 (-0.58%)
MU   50.65 (+1.28%)
CGC   2.75 (-1.08%)
F   11.27 (-1.74%)
GE   62.19 (-0.86%)
DIS   95.13 (-2.38%)
AMC   7.05 (-0.70%)
PYPL   86.68 (-2.28%)
PFE   44.07 (-0.20%)
NFLX   236.63 (-1.28%)
NASDAQ:AVXL

Anavex Life Sciences - AVXL Stock Forecast, Price & News

$10.34
+0.59 (+6.05%)
(As of 09/30/2022 03:34 PM ET)
Add
Compare
Today's Range
$9.58
$10.64
50-Day Range
$8.90
$11.87
52-Week Range
$7.13
$23.73
Volume
31,556 shs
Average Volume
752,294 shs
Market Capitalization
$805.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.67

Anavex Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
269.7% Upside
$38.67 Price Target
Short Interest
Bearish
12.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
1.41mentions of Anavex Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

691st out of 1,097 stocks

Biological Products, Except Diagnostic Industry

115th out of 172 stocks

AVXL stock logo

About Anavex Life Sciences (NASDAQ:AVXL) Stock

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

Anavex Life Sciences (NASDAQ:AVXL) Trading 4.5% Higher
Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences Q2 2022 Earnings Preview
See More Headlines
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Company Calendar

Last Earnings
8/09/2022
Today
9/30/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/23/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.67
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+274.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-37,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.99 per share

Miscellaneous

Free Float
69,369,000
Market Cap
$805.90 million
Optionable
Optionable
Beta
0.82

Key Executives

  • Dr. Christopher U. Missling M.B.A. (Age 56)
    M.S., Ph.D., Chairman, Pres, CEO & Sec.
    Comp: $671.6k
  • Ms. Sandra Boenisch CPA (Age 41)
    CPA, CGA, Principal Financial Officer & Treasurer
    Comp: $158.3k
  • Mr. Stephan Toutain (Age 56)
    Chief Operating Officer
  • Dr. Walter E. Kaufmann M.D.
    Chief Scientific Officer
  • Dr. Emmanuel O. Fadiran RPh
    Ph.D., Sr. VP of Regulatory Affairs
  • Clint Tomlinson
    VP of Corp.
  • Dr. Adebayo Laniyonu Ph.D.
    Sr. VP of Nonclinical Devel.
  • Dr. Edward R Hammond M.D.
    M.P.H., Ph.D., Chief Medical Officer













AVXL Stock - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings
or view top-rated stocks.

What is Anavex Life Sciences' stock price forecast for 2022?

3 brokers have issued 12 month target prices for Anavex Life Sciences' shares. Their AVXL share price forecasts range from $34.00 to $42.00. On average, they predict the company's share price to reach $38.67 in the next twelve months. This suggests a possible upside of 268.3% from the stock's current price.
View analysts price targets for AVXL
or view top-rated stocks among Wall Street analysts.

How have AVXL shares performed in 2022?

Anavex Life Sciences' stock was trading at $17.34 at the beginning of the year. Since then, AVXL stock has decreased by 39.4% and is now trading at $10.50.
View the best growth stocks for 2022 here
.

When is Anavex Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 23rd 2022.
View our AVXL earnings forecast
.

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp. (NASDAQ:AVXL) issued its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. During the same quarter in the prior year, the company posted ($0.14) earnings per share.

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), CytRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How do I buy shares of Anavex Life Sciences?

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $10.50.

How much money does Anavex Life Sciences make?

Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $818.37 million. The biotechnology company earns $-37,910,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.

This page (NASDAQ:AVXL) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.